Sanctuary Advisors LLC Sells 9,361 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sanctuary Advisors LLC trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 20.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,938 shares of the biopharmaceutical company's stock after selling 9,361 shares during the period. Sanctuary Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $37,779,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. International Assets Investment Management LLC lifted its position in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock valued at $926,078,000 after buying an additional 879,916 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $127,489,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Regeneron Pharmaceuticals by 23.8% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company's stock worth $525,804,000 after purchasing an additional 96,266 shares during the period. TD Asset Management Inc boosted its position in Regeneron Pharmaceuticals by 30.4% during the 2nd quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company's stock worth $369,484,000 after purchasing an additional 82,034 shares during the period. Finally, Icon Wealth Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 18,342.0% in the 3rd quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company's stock valued at $79,874,000 after purchasing an additional 75,569 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on REGN shares. StockNews.com downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a research report on Friday, November 1st. Citigroup started coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, November 14th. They set a "neutral" rating and a $895.00 price target for the company. Finally, JPMorgan Chase & Co. cut their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $1,099.90.

Regeneron Pharmaceuticals Trading Down 4.1 %

NASDAQ:REGN traded down $32.03 during trading hours on Thursday, hitting $740.97. 923,616 shares of the stock were exchanged, compared to its average volume of 555,558. The company's 50 day moving average is $860.87 and its two-hundred day moving average is $1,007.41. The company has a market capitalization of $81.43 billion, a P/E ratio of 19.13, a price-to-earnings-growth ratio of 3.00 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a twelve month low of $735.95 and a twelve month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.